金城医药：米拉贝隆化学原料药上市申请获批

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used for treating overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical announced on September 23 that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] Industry Summary - Mirabegron is classified as a selective β-3 adrenergic receptor agonist and is indicated for the treatment of overactive bladder (OAB), which includes symptoms like urinary incontinence, urgency, and frequency [1]